CNO Financial Group Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw all director nominees elected, executive compensation approved, and the accounting firm ratified. Strong 2025 results included double-digit earnings and sales growth, with a focus on continued profitability and ROE expansion through 2027.
-
Operating EPS rose 33% year-over-year, with strong sales and agent growth across divisions. ROE reached 13.1%, and capital position remains robust. Guidance for 2026 is affirmed, with expectations to raise ROE targets for 2027.
Fiscal Year 2025
-
Record sales and earnings growth exceeded 2025 guidance, driven by strong insurance margins, investment income, and agent productivity. Outlook for 2026 remains positive, with continued focus on Medicare Supplement and disciplined capital deployment.
-
Strong Q3 results featured record new annualized premiums, double-digit sales growth, and a 16% rise in operating EPS. Strategic actions include exiting the fee services business and executing a second Bermuda reinsurance treaty, both expected to boost ROE and future earnings.
-
Strong growth in life, health, and annuity sales is driven by a resilient, multi-channel distribution model and a focus on developing agents into financial advisors. Wealth management and cross-selling are expanding, with secular trends and digital strategies supporting future momentum.
-
Record new annualized premiums and strong double-digit sales growth drove robust operating earnings and ROE improvement. Investment income and book value per share increased, while capital and liquidity remained above targets. Guidance for 2025 was reaffirmed.
-
Operating earnings per share rose sharply year-over-year, driven by strong sales, investment income, and disciplined capital management. Guidance for 2025 and long-term ROE improvement was reaffirmed despite macroeconomic uncertainty, with robust segment growth and continued share buybacks.
Fiscal Year 2024
-
Exceptional 2024 results featured record sales, strong earnings growth, and robust capital returns. Guidance calls for continued ROE expansion, technology investment, and disciplined capital management, with favorable market trends supporting long-term growth.
-
Operating earnings per share rose 26% year-over-year, with strong sales momentum, robust investment income, and record annuity and worksite results. Guidance for 2024 EPS and excess cash flow was raised, reflecting continued business strength and capital discipline.
-
The company has successfully transitioned to a growth-focused model, emphasizing the middle market and leveraging a unique mix of products and distribution channels. Recent efficiency initiatives, strong agent productivity, and disciplined capital deployment support ongoing growth and profitability.
-
Q2 2024 saw robust earnings and sales growth, with operating EPS up 94% and strong performance across all business segments. Guidance for full-year EPS and cash flow was raised, capital and liquidity remain strong, and agent productivity and count continue to grow.